Silvercrest Asset Management
NPCE icon

Silvercrest Asset Management’s Neuropace NPCE Stock Holding History

Silvercrest Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.47M Sell
344,124
-15,941
-4% -$257K 0.04% 442
2026
Q1 		$4.73M Sell
360,065
-36,554
-9% -$548K 0.03% 434
2025
Q4 		$6.12M Buy
396,619
+97,232
+32% +$1.3M 0.04% 407
2025
Q3 		$3.09M Buy
299,387
+641
+0.2% +$6.04K 0.02% 482
2025
Q2 		$3.33M Sell
298,746
-117,791
-28% -$1.47M 0.02% 479
2025
Q1 		$5.12M Buy
+416,537
New +$5.21M 0.04% 406

Other funds holding NPCE

Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
First Light Asset Management
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Silvercrest Asset Management's NPCE Position: Q2 2026 in Review

Silvercrest Asset Management reduced its Neuropace (NPCE) stake by 4.4% in Q2 2026, selling an estimated $257K and leaving 344,124 shares worth $5.47M. The position accounts for 0.04% of the portfolio, ranked #442.

Silvercrest Asset Management first reported a position in NPCE in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.12M in Q4 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Silvercrest Asset Management held 344,124 shares of Neuropace worth $5.47M as of Q2 2026.
  • Silvercrest Asset Management sold 15,941 Neuropace shares in Q2 2026, an estimated $257K.
  • Neuropace made up 0.04% of Silvercrest Asset Management's portfolio in Q2 2026, its #442 holding.
  • Silvercrest Asset Management first reported a position in Neuropace in Q1 2025 and has held it in 6 quarters since.
  • Silvercrest Asset Management's Neuropace position peaked at $6.12M in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.